Petros Pharmaceuticals Stock Today
| PTPI Stock | USD 0.27 0 0.37% |
Performance0 of 100
| Odds Of DistressOver 85
|
Petros Pharmaceuticals is trading at 0.271 as of the 28th of November 2024. This is a 0.37 percent increase since the beginning of the trading day. The stock's open price was 0.27. Petros Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Petros Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of December 2020 | Category Healthcare | Classification Health Care |
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on mens health therapeutics. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 10.01 M outstanding shares of which 199.19 K shares are at this time shorted by private and institutional investors with about 0.72 trading days to cover. More on Petros Pharmaceuticals
Moving together with Petros Stock
| 0.69 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Petros Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Petros Stock Highlights
| President Officer | Fady MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPetros Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Petros Pharmaceuticals' financial leverage. It provides some insight into what part of Petros Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Petros Pharmaceuticals (PTPI) is traded on NASDAQ Exchange in USA. It is located in 1185 Avenue of the Americas, New York, NY, United States, 10036 and employs 21 people. Petros Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.68 M. Petros Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 10.01 M outstanding shares of which 199.19 K shares are at this time shorted by private and institutional investors with about 0.72 trading days to cover.
Petros Pharmaceuticals currently holds about 13.3 M in cash with (7.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.64, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Petros Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationPetros Pharmaceuticals holds 8.1 pct. of its outstanding shares held by insiders and 2.2 pct. owned by third-party entities.
Check Petros Ownership Details
Petros Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Fidelity Management And Research Company | 2024-06-30 | 0.0 | |
| Citadel Advisors Llc | 2024-06-30 | 0.0 | |
| Newbridge Financial Services Group, Inc. | 2024-06-30 | 0.0 | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | |
| Virtu Financial Llc | 2024-06-30 | 70.3 K | |
| Two Sigma Securities, Llc | 2024-06-30 | 53.9 K | |
| Geode Capital Management, Llc | 2024-09-30 | 37.5 K | |
| Vanguard Group Inc | 2024-09-30 | 31.8 K | |
| Blackrock Inc | 2024-06-30 | 16.5 K | |
| Tower Research Capital Llc | 2024-06-30 | 3.3 K |
Petros Pharmaceuticals Historical Income Statement
Petros Stock Against Markets
Petros Pharmaceuticals Corporate Management
| Mitchell MBA | VP Officer | Profile | |
| Keith Lavan | Advisor | Profile | |
| John Shulman | Executive Board | Profile | |
| Robert Weinstein | Interim Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Petros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Petros Pharmaceuticals. If investors know Petros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Petros Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.80) | Revenue Per Share 0.99 | Quarterly Revenue Growth (0.29) | Return On Assets (0.31) | Return On Equity (0.64) |
The market value of Petros Pharmaceuticals is measured differently than its book value, which is the value of Petros that is recorded on the company's balance sheet. Investors also form their own opinion of Petros Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Petros Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Petros Pharmaceuticals' market value can be influenced by many factors that don't directly affect Petros Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Petros Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Petros Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Petros Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.